KR20150000874A - 비수성 액체 조성물 - Google Patents

비수성 액체 조성물 Download PDF

Info

Publication number
KR20150000874A
KR20150000874A KR20147023427A KR20147023427A KR20150000874A KR 20150000874 A KR20150000874 A KR 20150000874A KR 20147023427 A KR20147023427 A KR 20147023427A KR 20147023427 A KR20147023427 A KR 20147023427A KR 20150000874 A KR20150000874 A KR 20150000874A
Authority
KR
South Korea
Prior art keywords
aqueous liquid
liquid composition
drug
range
tocopherol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147023427A
Other languages
English (en)
Korean (ko)
Inventor
가즈히토 야마다
알토 얼티
메히틸트 부메슈터
Original Assignee
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산텐 세이야꾸 가부시키가이샤 filed Critical 산텐 세이야꾸 가부시키가이샤
Publication of KR20150000874A publication Critical patent/KR20150000874A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR20147023427A 2012-01-31 2013-01-30 비수성 액체 조성물 Withdrawn KR20150000874A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012018062 2012-01-31
JPJP-P-2012-018062 2012-01-31
PCT/JP2013/051951 WO2013115201A1 (ja) 2012-01-31 2013-01-30 非水性液体組成物

Publications (1)

Publication Number Publication Date
KR20150000874A true KR20150000874A (ko) 2015-01-05

Family

ID=48905235

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147023427A Withdrawn KR20150000874A (ko) 2012-01-31 2013-01-30 비수성 액체 조성물

Country Status (12)

Country Link
US (1) US20150011518A1 (cg-RX-API-DMAC7.html)
EP (1) EP2810657B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013177372A (cg-RX-API-DMAC7.html)
KR (1) KR20150000874A (cg-RX-API-DMAC7.html)
CN (1) CN104080478A (cg-RX-API-DMAC7.html)
CA (1) CA2861261A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491453A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN06911A (cg-RX-API-DMAC7.html)
PH (1) PH12014501689A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201606271RA (cg-RX-API-DMAC7.html)
TW (1) TW201336526A (cg-RX-API-DMAC7.html)
WO (1) WO2013115201A1 (cg-RX-API-DMAC7.html)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
AU6919598A (en) * 1997-04-17 1998-11-13 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4496406B2 (ja) 2003-03-07 2010-07-07 参天製薬株式会社 4−ピリジルアルキルチオ基を置換基として有する新規化合物
CN1897918A (zh) * 2003-11-17 2007-01-17 阿尔萨公司 包含两亲性分子作为混悬载体的组合物和剂型
JP4626353B2 (ja) 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した4−ピリジルアルキルチオ基を有する新規環式化合物
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
EP1843746B1 (en) * 2005-01-14 2011-03-16 Camurus Ab Somatostatin analogue formulations
PL1845942T3 (pl) * 2005-01-14 2014-07-31 Camurus Ab Preparaty analogu GnRH
AU2005325510B2 (en) * 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
JP4585978B2 (ja) 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
JP4834441B2 (ja) 2005-03-31 2011-12-14 参天製薬株式会社 ピリミジニルアルキルチオ基を有する新規環式化合物
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
JP4825636B2 (ja) 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2−ジヒドロキノリン誘導体
JP5054996B2 (ja) 2006-03-14 2012-10-24 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2,3,4−テトラヒドロキノキサリン誘導体
KR20090086539A (ko) 2006-11-14 2009-08-13 산텐 세이야꾸 가부시키가이샤 (치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체
EP2128156A4 (en) 2007-01-29 2011-05-18 Santen Pharmaceutical Co Ltd NEW OXADIAZOL DERIVATIVES AND THIADIAZONE DERIVATIVES WITH THE NEOVASCULARIZATION HEMMENDER EFFECT
EP2151436B1 (en) 2007-05-29 2013-04-24 Santen Pharmaceutical Co., Ltd Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
WO2009035068A1 (ja) 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規1,3,3-トリメチル-7-フェニル-3,4-ジヒドロ-1h-キノキサリン-2-オン誘導体
AU2010271746B2 (en) 2009-07-17 2014-07-03 Santen Pharmaceutical Co., Ltd. 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol

Also Published As

Publication number Publication date
PH12014501689A1 (en) 2014-10-20
EP2810657A4 (en) 2015-07-29
US20150011518A1 (en) 2015-01-08
EA201491453A1 (ru) 2014-12-30
WO2013115201A1 (ja) 2013-08-08
IN2014DN06911A (cg-RX-API-DMAC7.html) 2015-05-15
EP2810657B1 (en) 2016-09-21
CA2861261A1 (en) 2013-08-08
SG10201606271RA (en) 2016-09-29
SG11201404230QA (en) 2014-10-30
CN104080478A (zh) 2014-10-01
TW201336526A (zh) 2013-09-16
EP2810657A1 (en) 2014-12-10
JP2013177372A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
Boyd et al. Hexosomes formed from glycerate surfactants—Formulation as a colloidal carrier for irinotecan
US20230248720A1 (en) Long Acting Injectable Formulations
JP7402301B2 (ja) 水混和性の薬学的に許容可能な溶媒の水性ブレンド中のロフルミラストの医薬組成物
ES2844581T3 (es) Método para mejorar la solubilidad acuosa de fármacos insolubles en agua o ligeramente solubles en agua
MX2012003985A (es) Composiciones topicas tetraciclina.
Iwanaga et al. Application of organogels as oral controlled release formulations of hydrophilic drugs
CN104095806A (zh) 局部组合物
JP6094388B2 (ja) ペメトレキセドを含む注射用組成物
CN107847437B (zh) 用于治疗疼痛的塞来昔布口服组合物
CA3029569A1 (en) Methods for the preparation of a levothyroxine solution
KR101996597B1 (ko) 두타스테리드와 타다라필을 용해시킨 경구용 캡슐 제형의 복합제제
CN104507467A (zh) 含紫杉烷系活性成分的液体组合物、其制造方法及液体制剂
El-Houssieny et al. Formulation and evaluation of clotrimazole from pluronic F 127 gels.
US20090227552A1 (en) Fulvestrant formulations
ES2276110T3 (es) Formulacion farmaceutica que incluye un inhibidor de renina no peptidico y un tensioactivo.
EP2810657B1 (en) Non-aqueous liquid composition
JP5503939B2 (ja) アゼラスチン塩酸塩含有カプセル剤
JP4686144B2 (ja) 油脂性軟膏剤
JPH0536412B2 (cg-RX-API-DMAC7.html)
CN101106995B (zh) 在非水极性溶剂中增加溶解度的10-羟基喜树碱类化合物的药物制剂
CN101912362A (zh) 一种替尼泊苷静脉注射用脂肪乳预乳化浓缩液及其制备方法
JP5223307B2 (ja) 坐剤
US8044104B2 (en) Prostaglandin derivative-containing aqueous liquid preparation
AU2016393213B2 (en) Pemetrexed formulations
Rashwan et al. FABRICATION OF TOPICAL BACLOFEN LOADED EMULGEL: CHARACTERIZATION, OPTIMIZATION USING 23 FULL FACTORIAL DESIGN AND IN VIVO ANTI-INFLAMMATORY ACTIVITY

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140821

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid